Abstract Library

#4429 Liver transplantation for pancreatic neuroendocrine tumour: A case report

Introduction: The use of liver transplantation for metastatic neuroendocrine tumours is still being explored.

Conference:

Presenting Author: Wang H

Authors: Wang H, Tan H, Zhao H, Chi Y,

Keywords: pancreatic neuroendocrine tumour, liver transplantation, STEM,

#4170 Analysis of the efficacy of STEM chemotherapy in patients with metastatic paraganglioma

Introduction: Paraganglioma is a special kind of neuroendocrine tumor, located outside the adrenal gland, about 35-40% is related to heredity and has corresponding germline mutation. The therapeutic response is different from that of neuroendocrine tumors derived from gastrointestinal and pancreas.

Conference:

Presenting Author: Tan H

Authors: Tan H, Zhao H, Shi S, Jiang L, Chi Y,

Keywords: metastatic paraganglioma, STEM, efficacy,

#4148 S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumors (STEM): A randomised, open-label, multicentre phase 2 trial

Introduction: There are currently limited systemic treatment options for patients with advanced neuroendocrine tumors (NETS) and the efficacy of existing treatments is sub-optimal.

Conference:

Presenting Author:

Authors: Chi Y, Song L, Liu W, Zhou Y, Miao Y,

Keywords: S-1, temozolomide, thalidomide, neuroendocrine tumor,

#3242 Establishment and characterization of a new neuroendocrine carcinoma cell model

Introduction: The development of treatment strategies for neuroendocrine carcinomas (NEC) requires in vitro models expressing NEC–specific targets. The CXC Chemokine Receptor Type 4 (CXCR4), that is expressed in NEC with decreasing differentiation, as well as factors involved in chemotherapy resistance may represent such targets.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Weich A

Authors: Weich A, Schreiner J, Rogoll D, Werner R, Meining A,

Keywords: neuroendocrine, net, CXCR4, Wnt signalling, beta-catenin, BON-1, QGP-1,

#3152 Vasostatin-1 as pancreatic neuroendocrine tumor (PanNET) biomarker: A comparison between preoperative and postoperative measurements

Introduction: No reliable biomarkers are currently available for pancreatic neuroendocrine tumors (PanNET). Vasostatin-1 (VS-1), the N-terminal fragment of Chromogranin A (CgA), seems to be more reliable than CgA as its plasma levels are not altered by proton pump inhibitors. An association between preoperative VS-1 and pathological features of aggressiveness was previously reported in a cohort of patients with resected nonfunctioning (NF)-PanNET.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Andreasi V

Authors: Andreasi V, Partelli S, Manzoni M, Colombo B, Muffatti F,

Keywords: pancreatic neuroendocrine tumor, biomarker, chromogranin A, vasostatin-1,